Public health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2.

This fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID.

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

The U.S. Food and Drug Administration (FDA) is unlikely to renew the authorization granted to use Pfizer (NYSE:PFE) and BioNTech’s (BNTX) COVID-19 vaccine in young children this fall, The Guardian ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions -- by its April 1 ...

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

Novavax COVID vaccine shows strong efficacy The biotechnology company announced Monday that its stage three clinical trial showed overall efficacy of 90.4% against COVID-19.